Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma ...

The FDA has approved Pfizer's BCMAxCD3 bispecific antibody Elrexfio as another off-the-shelf treatment option for people with multiple myeloma who have exhausted at least four prior lines of therapy.

Olivier Nataf, global head, oncology.at Sanofi, commented: “In recent years, new multiple myeloma cases have increased steadily in Japan and other Asian-Pacific nations, creating a need for new ...